Cellegy Pharmaceuticals and PanGeo Pharma have entered into an agreementunder which the latter will make the former's Tostrex (testosterone gel), developed for the treatment of hypogonadism, at its Montreal, Canada, manufacturing facility, reports the Montreal Gazette.
PanGeo will supply certain minimum quantities of Tostrex, which is currently in Phase III clinical trials, over a five-year period after final US Food and Drug Administration approval. Financial terms of the agreement were not disclosed.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze